Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2026 · 10-Q
Revenue$104.00K$104.00K−14.0% vs Q2 2025 Net Income-$9.23M-$9.23MN/M vs Q2 2025 EPS Diluted-$0.14-$0.14N/M vs Q2 2025 Operating Income-$9,615,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-9245.2%+2967.2 pt vs Q2 2025
Net margin-8876.9%+2646.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end